MX2023000004A - Formulaciones para promover la hidratacion y metodos de uso de las mismas. - Google Patents

Formulaciones para promover la hidratacion y metodos de uso de las mismas.

Info

Publication number
MX2023000004A
MX2023000004A MX2023000004A MX2023000004A MX2023000004A MX 2023000004 A MX2023000004 A MX 2023000004A MX 2023000004 A MX2023000004 A MX 2023000004A MX 2023000004 A MX2023000004 A MX 2023000004A MX 2023000004 A MX2023000004 A MX 2023000004A
Authority
MX
Mexico
Prior art keywords
barrier function
intestinal barrier
formulations
need
hydration
Prior art date
Application number
MX2023000004A
Other languages
English (en)
Inventor
Sadasivan Vidyasagar
Astrid Grosche
Stephen Gatto
Xiaodong Xu
Shanshan Lin
Robert Kenefick
Samuel Cheuvront
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of MX2023000004A publication Critical patent/MX2023000004A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52Adding ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Formulaciones que comprenden aminoácidos libres específicos útiles para promover la hidratación y/o la función de barrera intestinal en un sujeto que lo necesita se describen en el presente documento. Dichas formulaciones y métodos usando los mismos son útiles para promover la hidratación y/o la función de barrera intestinal en un sujeto que lo necesite. Dichos sujetos pueden estar sanos, pero con la necesidad de una formulación que promueva la hidratación rápida (por ejemplo, dentro de los siguientes 15-90 minutos después de la administración) o promueve la función de la barrera intestinal; o dichos sujetos se pueden ver afectados por una padecimiento o enfermedad asociada con la deshidratación o la función de barrera intestinal alterada, respectivamente. El uso de formulaciones de aminoácidos descritas en el presente documento para promover la hidratación y/o la función de barrera intestinal en un sujeto que lo necesita, para el tratamiento de trastornos o enfermedades asociadas con la deshidratación y/o la función de barrera intestinal alterada, y en la preparación de un medicamento para el tratamiento de trastornos o enfermedades asociadas con la deshidratación y/o la función de barrera intestinal alterada se incluyen en el presente documento.
MX2023000004A 2020-07-02 2021-07-01 Formulaciones para promover la hidratacion y metodos de uso de las mismas. MX2023000004A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063047300P 2020-07-02 2020-07-02
PCT/US2021/040090 WO2022006397A1 (en) 2020-07-02 2021-07-01 Formulations for promoting hydration and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2023000004A true MX2023000004A (es) 2023-03-06

Family

ID=79314908

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000004A MX2023000004A (es) 2020-07-02 2021-07-01 Formulaciones para promover la hidratacion y metodos de uso de las mismas.

Country Status (11)

Country Link
US (1) US20230149335A1 (es)
EP (1) EP4175662A4 (es)
JP (1) JP2023533617A (es)
KR (1) KR20230047371A (es)
CN (1) CN116194136A (es)
AU (1) AU2021300188A1 (es)
BR (1) BR112022027124A2 (es)
CA (1) CA3184691A1 (es)
IL (1) IL299488A (es)
MX (1) MX2023000004A (es)
WO (1) WO2022006397A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11878073B1 (en) * 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010017403A2 (en) * 2008-08-06 2010-02-11 Immunopath Profile, Inc. Therapeutic compositions, devices and methods for observing treated tissues
KR20170084354A (ko) * 2010-09-24 2017-07-19 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 위장 기능을 증진시키기 위한 물질 및 방법
AU2013216871B2 (en) * 2012-02-08 2017-08-17 University Of Florida Research Foundation, Inc. Materials and methods for treating diarrhea
CA3039514C (en) * 2016-10-04 2022-01-25 University Of Florida Research Foundation, Incorporated Amino acid compositions and uses thereof
WO2019070753A1 (en) * 2017-10-02 2019-04-11 University Of Florida Research Foundation, Incorporated AMINO ACID COMPOSITIONS AND METHODS FOR TREATING DIARRHEA

Also Published As

Publication number Publication date
IL299488A (en) 2023-02-01
JP2023533617A (ja) 2023-08-03
EP4175662A4 (en) 2024-07-17
CN116194136A (zh) 2023-05-30
KR20230047371A (ko) 2023-04-07
AU2021300188A1 (en) 2023-02-02
WO2022006397A1 (en) 2022-01-06
BR112022027124A2 (pt) 2023-03-07
EP4175662A1 (en) 2023-05-10
CA3184691A1 (en) 2022-12-30
US20230149335A1 (en) 2023-05-18

Similar Documents

Publication Publication Date Title
SG162788A1 (en) Self-buffering protein formulations
Fidler et al. Slipped upper femoral epiphysis following treatment with human growth hormone
MX2020010130A (es) Formulacion y metodo de preparacion.
MX2017001682A (es) Composiciones de alergenos alimentarios.
CY1122427T1 (el) Συνθεση για την προφυλαξη απο καντιντιαση
MX2023010328A (es) Composiciones de medicamentos a base de peptido de colageno y metodos y dispositivos para su produccion y uso.
HUP0102479A2 (hu) Neisseria meningitidis-ből származó BASBO29-polinukleotid(ok) és polipeptidek
MX2023000004A (es) Formulaciones para promover la hidratacion y metodos de uso de las mismas.
Wollina et al. Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma
Bali et al. Cyclosporine reduces sclerosis in morphea: a retrospective study in 12 patients and a literature review
US20140112937A1 (en) Use of an agent consisting of antibodies and/or insulin-like growth factor antagonists
Walusinski et al. Augustin Morvan (1819–1897), a little-known rural physician and neurologist
MX2023000499A (es) Tratamiento de enfermedades inflamatorias con anticuerpos anti-factor tisular.
Brazzelli et al. Bleomycin-induced flagellate dermatitis: report of four paediatric cases.
WO2019055776A3 (en) Compositions and methods for treatment of diseases involving cxcl1 function
TUFFANELLI A clinical trial with dimethyl sulfoxide in scleroderma
MX2021011328A (es) Método para tratar la psoriasis en sujetos pediátricos con anticuerpo anti-il12/il23.
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
Levy et al. Tinea versicolor associated with etanercept therapy
Bronshteyn et al. Human Dirofilariasis repens-migratory cutaneous and visceral helminthiasis: new data of" the old" disease. Analysis of cases and review
Anagnostou et al. Pharmacokinetic interactions of selective serotοnin reuptake inhibitors
Pandya et al. Chikungunya and Its oral manifestation: A comprehensive review
Srinivasa et al. INTRALESIONAL BCG: AN ANSWER TO RECALCITRANT WARTS
RU2586280C1 (ru) Способ комплексной терапии функциональных нарушений пищеварения у детей дошкольного возраста
Dalewski et al. Clinical Study Comparison of Early Effectiveness of Three Different Intervention Methods in Patients with Chronic Orofacial Pain: A Randomized, Controlled Clinical Trial